Weight LossMar 27, 2026, 8:15 AM ETStructure Therapeutics Inc. (GPCR) StockBrendan O'Boyle2.83K FollowersCommentsStructure Therapeutics reported Phase 2 data for Aleniglipron, showing 16% weight loss at 44 weeks with strong tolerability and no safety signals.Aleniglipron’s best-in-class oral efficacy, low discontinuation, and clean safety profile position GPCR as a formidable challenger or acquisition target in obesity therapeutics.Significant risks remain: long, costly Phase 3 trials, uncertain durability of tolerability, and the need for additional capital before commercialization.I rate GPCR a compelling Buy for risk-tolerant investors seeking asymmetric upside, given its de-risked asset and current valuation modestly above pre-Phase 2 levels.Kathrin Ziegler/DigitalVision via Getty ImagesLast week, Structure Therapeutics (GPCR) reported top-line data from its Phase 2 trial (ACCESS II) for Aleniglipron, a small molecule GLP-1 agonist for weight loss. The data were well received by the market, with theThis article was written byBrendan O'Boyle2.83K FollowersBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Comments